in the late 1980's, 3 two other clinical challenges emerged, that is, overdiagnosis and overtreatment. 4 Therefore, an accurate risk stratification tool at the time of diagnosis is the cornerstone of clinical decision making paving the way for personalized management of PCa.
Since the mid-1990's there was a plethora of pre-and posttreatment predictive models to propose risk assessment of localized PCa of both clinical and biochemical outcome. 5 These models depend either completely or partially on PSA, clinical tumor stage (cT), and
Gleason score (GS).
Whereas GS is still the best prognostic indicator in PCa management, 6 discrepancy between GS in the diagnostic needle biopsies and the prostatectomy specimens, 7 inter-and intraobserver variability, 8 and sampling error 9 are among its most common pitfalls in daily practice.
These models are challenged by the nature of PCa as a heterogeneous disease. Patients with high risk PCa have an approximate 50% risk of progression at 5 years 10 while 70% of the patients with PCa under the active surveillance strategy (AS) can avoid active treatment during 15 years of follow-up. 11 Moreover, throughout treatment it may also be difficult as well as doubtful to rely on a model based only on the PCa characteristics at the time of diagnosis.
More robust risk assessment tools are therefore needed in the management of PCa and with the advent of bio-informatics, temporal genomic analysis may now be incorporated into the predictive tools to improve stratification accuracy. Since heterogeneity of PCa tissue is a well-known clinical challenge in PCa management, liquid biomarkers may represent an alternative diagnostic and prognostic tool in PCa. 12 MicroRNAs (miRNAs) are non-coding single-stranded evolutionarily conserved RNA molecules comprising 19-24 nucleotides in length that regulate gene expression both at the transcriptional and post transcriptional level. 13, 14 Recently, more than 1900 human miRNAs have been identified (www.mirbasae.org, March 2018), their genes being located within protein-coding genes or in intergenic regions; either alone or in clusters. 15 MicroRNAs play a crucial rule in both physiological and pathological cellular processes such as cell cycle regulation, 16 development, 17 and apoptosis, 18 and in cancer development and progression. 19 They are quite stable in different biological materials and in various storage conditions. 20 They are dysregulated in many type of cancers, 21 including PCa 22 and available for sampling through a variety of body fluids. 23 Consequently, miRNAs have attracted attention as candidates for minimally invasive biomarkers in PCa.
The aim of this study was to illustrate the change of circulating miRNAs after management of newly diagnosed patients with localized/locally advanced PCa and to analyze the correlation between circulating miRNAs and common risk parameters (PSA, GS, cT, and the European Association of Urology (EAU) risk profile 24 ).
| MATERIAL AND METHODS

| Patients
As described in our previous work (validation cohort), 25 all patients were referred to the Department of Urology either at Vejle Hospital or Esbjerg Hospital, Denmark, between September 2015 and May 2017.
All participants provided informed written consent.
In total, 149 patients were prospectively included in this study. 
| Blood collection and storage
Two venous blood samples were collected from all patients; baseline (prior to TRUS) and follow-up (after 6 months). Sampling was performed by skilled phlebotomists using a minimum of venous stasis to prevent hemolysis. Whole blood was collected into 9 mL To reduce the risk of hemolysis and diminish the risk of release of miRNAs from other intravascular cell compartments, all blood samples were handled within the first 2 h after sample collection.
Also, all samples were evaluated for hemolysis by A414 measure and approx. 85% of all values were ≤ log (abs) = 0.25, which corresponds to less than 1% hemolysis when comparing to recommendations. There were 32 samples (11%) above 0.25 and below 0.5. Evaluation of these samples did not show any trends toward neither higher nor lower Ct values and therefore, they were not excluded. In only 11 samples (4%) the hemolysis index was relatively high (≥ 0.5) and these samples were excluded from further data analysis.
| Selected miRNA targets
In the present study a panel of four microRNAs was selected; miRNA-21, -93, -125b, and miRNA-221. This choice was based on results from our previous work 25, 27 and a comprehensive review of the literature (Supplementary Table SI) . Lightcycler®96. In brief, reverse transcription (RT) was performed in three steps, first a poly-A tailing, then adaptor ligation reaction followed by a universal RT. After RT, we performed targeted pre-amplification according to protocol and the final cDNA was diluted 10 times before mixing the qPCR reaction. All qPCR reactions were performed in triplicate. Results were analyzed using Roche Lightcycler®96 Software.
We have previously 25 established both miRNA-17 and miRNA-191 as suitable internal controls, that is, they displayed stable expression levels throughout all previous samples as judged by manual review and according to the Normfinder algorithm. 28 Both miRNAs had previously proven suitable as reference RNA targets. 29 In this study, however, the commercial miRNA-191 single assay did not perform satisfactorily and was discarded from further use leaving miRNA-17 as the internal control miRNA. Samples were distributed across several qPCR plates and in order to facilitate individual comparison between samples on different plates we used plate-toplate variation controls.
| Statistical analysis
Data are presented as means of three technical replicates per plasma sample from each patient. The fold change of plasma miRNA was calculated based on the threshold cycle (Ct) value using the following formula:
ΔCt ¼ mean Ct value of target miRNA À mean Ct value of miRNA À 17
Results were linearized using 2
, which was subsequently applied in the statistical analysis.
Samples with missed Ct measurements in either baseline or follow-up samples were dismissed. However, Ct values above 35 were dismissed only from baseline plasma samples, since a change in miRNAs in plasma was expected in follow-up samples.
A summary of all dismissed values is showed in supplementary ).
Up/downregulation of plasma miRNA levels in baseline compared with follow-up samples in both the observational and the interventional groups was illustrated by boxplots.
All analyses were performed in STATA version 15.1 (STATA Corp LLC, TX, USA), and correlations/differences were considered statistically significant when the P-value was less than 0.05.
3 | RESULTS
| Patient characteristics
While mean PSA level was significantly lower, mean prostate volume was significantly higher in the observation cohort compared to the intervention cohort.
The clinicopathological characteristics of all PCa patients are presented in Table 1 .
| Changes in circulating miRNAs from baseline to follow-up
The plasma levels of both miRNA-93 and miRNA-221 were significantly downregulated in the follow-up samples compared to the baseline samples in the interventional group (z = −2.738, P = 0.006 and z = −4.498, P < 0.001, respectively) (results regarding miRNA-93 has been published in our previous work. 25 The downregulation of miRNA-93 was more significant in the RT subgroup (z = −2.366, P = 0.018) than in the RARP subgroup (−2.169, P = 0.030). On the other hand, plasma levels of miRNA-221 was more downregulated in the RARP subgroup (z = −3.802, P = < 0.001) than in the RT subgroup (z = −2.197, P = 0.028).
In the observation group, miRNA-125b was downregulated whereas miRNA-221 tended to be upregulated in follow-up plasma samples compared to baseline samples (z = −2.656, P = 0.008 and z = 1.863, P = 0.063, respectively) ( Table 2 ).
There was no difference in baseline miRNA levels between the observation and intervention group (Supplementary Table SIII) .
The difference between baseline and follow-up samples in both groups is illustrated by box plots in Data regarding miRNA-93 in both intervention and observation cohort was published in our previous work (ref. 25 ).
| Correlation between miRNA plasma levels in baseline samples with diagnostic clinical characteristics
Baseline plasma levels of miRNA-125b were significantly correlated with both prebiopsy PSA (rho = 0.198, P = 0.043) and EAU risk profile Interestingly, the plasma levels of all miRNAs (except for miRNA-93)
were significantly correlated with patient age at the time of diagnosis (Table 3) .
| Correlation to post-operative pathological characteristics in the RARP subgroup
In the subgroup analysis of the baseline plasma level of miRNAs in patients who underwent RARP, miRNA-93 showed an almost significant correlation with prostatectomy GS (rho = 0.276, P = 0.058). Looking at pN, radicality of tumor resection (R), and pT, no correlation was observed with miRNAs levels in baseline plasma samples (Table 4 ).
| DISCUSSION
In this study we analyzed circulating miRNAs in two cohorts of localized/ locally advanced PCa patients; an intervention cohort (RARP, RT, or
Box plots illustrating the change in plasma miRNAs between follow-up samples and baseline in both the observation and intervention PCa group. Only significant fold change is supplied with a P-value. *Box plots regarding miRNA-93 in both intervention and observation cohort was published in our previous work (ref. 25 ). [Color figure can be viewed at wileyonlinelibrary.com] 
ADT) and an observation cohort (AS or WW). Both miRNA-93 and
miRNA-221 demonstrated a significant decrease in plasma levels after both RARP and RT but not after ADT treatment. In the observation cohort, the plasma level of miRNA-125b decreased significantly while there was a tendency toward an increase of miRNA-221.
Accumulating evidence shows that RT in cancer treatment, including PCa, can significantly change miRNA expression levels. [30] [31] [32] Leung et al found decrease levels of 16 miRNAs (including miRNA-221) in PC-3 PCa cells when exposed to different radiation doses compared to the parental cells. 33 To the best of our knowledge, this is the first study to demonstrate a change of plasma miRNAs level in PCa patients having received curative intent RT.
Change of circulating miRNA levels after radical surgery has also been reported previously in breast cancer, colon cancer, and PCa. [34] [35] [36] Mahn et al observed significant reduction of miRNA-16, -26a, and miRNA-195 serum levels after RARP in 37 localized PCa patients. 36 Kelly et al found post-RARP expression levels of miR-141 to decline to levels similar to those of the controls. 37 In prostatectomy specimens from 28 localized PCa patients, Lehmusvaara et al reported downregulation of 24 miRNAs and upregulation of another 28 miRNAs (including miRNA-125b) after neoadjuvant bicalutamide and goserelin, respectively, before RARP. 38 The mechanism of action of bicalutamide is quite different from goserelin. 39 Therefore one of the reasons for non-significant changes of miRNA plasma levels in our ADT cohort could be pooling of data from patients treated with either bicalutamide or goserelin in the same group. Another explanation could be different materials, as Lehmusvaara et al studied miRNA expression in formalinfixed and paraffin-embedded PCa tissue while plasma samples were used in the present study.
Previous studies have shown that miRNA-93 and miRNA-221 levels are upregulated in blood samples from localized PCa patients compared to healthy men. 25, 40, 41 We have observed a correlation between miRNA-93 expression in cancerous tissue and paired plasma samples from mPCa. 25 Therefore, the significant decline in both the miRNA-93 and miRNA-221 plasma level after intervention in this study underline the clinical importance of these miRNAs as oncomiRNAs and their potential role as biomarkers for PCa management.
The upregulation of miRNA-125b in PCa patients compared to healthy controls has been documented in many studies. 25, 42, 43 Singh et al. observed an increased level of miRNA-125b in PCa patients with biochemical relapse after RARP compared to those who were relapse free. As a result, it was hypothesized that the more aggressive the PCa, the higher the level of miRNA-125b in the plasma. 43 Therefore, the increase of miRNA-125b in the observation cohort in this study may be associated with the risk of metastatic spread to regional LN. However, the exact role of miRNA-125b in cancer is far from fully understood, yet. Currently, there are more than 100 statistical models available for risk stratification of localized/locally advanced PCa. However, many of them lack external validation, 46 and even though the models are strictly used, misclassification rates are still around 30%, leaving a limitation to the accurate identification of low-risk PCa patients. 47 Therefore, the use of continuous risk variables in these models rather than defined risk categories increases the accuracy.
48
Only miRNA-125b correlated with prebiopsy PSA in our study.
Guan et al did not observe any correlation between miRNA-21 and the diagnostic characteristics in mPCa patients (initial PSA, cT, or GS).
Investigating the serum level of 10 miRNAs (including miRNA-93) in localized/locally advanced PCa, Moltzahn et al could not demonstrate any correlation with PSA, GS, or even age. 41 However, we showed a significant correlation of miRNA-21, -125b, and miRNA-221 with patient age at time of PCa diagnosis. Both miRNA-21 and miRNA-125b have been shown to be involved in the aging process through an altered DNA damage response. 49 Interestingly, the plasma level of miRNA-93 was significantly correlated with prostatectomy GS but not with diagnostic GS, which emphasizes the discordance between needle biopsy GS and post-operative GS.
The prospective collection of blood samples, the different treatment modalities, and a participation rate of 100% for both sampling time points are the strengths of the current study. However, the relatively small sample size of the RT and ADT subgroups is considered a limitation in our study and the results should be seen as hypothesis generating.
The clinical importance of any promising biomarker in cancer in general and specifically in PCa is derived from its ability to better distinguish indolent from aggressive cases in a more individualized pattern rather than the "one size fits all" principle. Large-scale studies with long follow-up periods are essential to get more reliable results.
Prediction of treatment response is another challenge in PCa management where serial non-invasive liquid biopsies could be of great help in monitoring and observing the patients, since early detection of relapse/progression of PCa is an important factor for better control of the disease. 
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